Document Detail

Reproducibility studies and interlaboratory concordance for androgen assays in female plasma.
MedLine Citation:
PMID:  10794485     Owner:  NLM     Status:  MEDLINE    
We conducted studies to determine the magnitude and sources of variability in androgen assay results and to identify laboratories capable of performing such assays for large epidemiological studies. We studied androstanediol (ADIOL), androstanediol glucuronide (ADIOL G), androstenedione (ADION), androsterone glucuronide (ANDRO G), androsterone sulfate (ANDRO S), dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA S), dihydrotestosterone (DHT), and testosterone (TESTO). A single sample of plasma was obtained from five postmenopausal women, five premenopausal women in the midfollicular phase of the menstrual cycle, and five women in the midluteal phase, divided into aliquots, and stored at -70 degrees. Four sets of two coded aliquots from each woman were then sent to participating labs for analysis at monthly intervals over 4 months. Using the logarithm of assay measurements, we estimated the components of variance and three measures of reproducibility. The usual coefficient of variation is a function of the components that are under the control of the laboratory. The intraclass correlation between measurements for a given individual is the proportion of the total variability that is associated with individuals. The minimum detectable relative difference is important to evaluate study feasibility. Results suggest that a single sample of ADIOL G, DHEA, DHEA S, and ANDRO G (with two lab replicates per sample) can be used to discriminate reliably among women in a given menstrual phase or menopausal status. The results for DHT, TESTO, ADION, and ANDRO S are more problematic and suggest that the present measurement techniques should be used with care, especially with midluteal phase women. The results for ADIOL suggest that this assay is not yet ready for use in epidemiological studies.
T R Fears; R G Ziegler; J L Donaldson; R T Falk; R N Hoover; F Z Stanczyk; J B Vaught; M H Gail
Related Documents :
18551235 - An in vitro assay to screen for the sensitizing potential of xenobiotics.
24634395 - Advances in enantiomeric resolution on monolithic chiral stationary phases in liquid ch...
23763335 - Anti-proliferative and matrix metalloproteinase-2 inhibition of longkong (lansium domes...
18695745 - Qualification and application of an elisa for the determination of tamm horsfall protei...
20235135 - Study of retention mechanism of imidazolium-based ionic liquids in hplc.
15556505 - Hippophae rhamnoides l.: chromatographic methods to determine chemical composition, use...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology     Volume:  9     ISSN:  1055-9965     ISO Abbreviation:  Cancer Epidemiol. Biomarkers Prev.     Publication Date:  2000 Apr 
Date Detail:
Created Date:  2000-06-20     Completed Date:  2000-06-20     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9200608     Medline TA:  Cancer Epidemiol Biomarkers Prev     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  403-12     Citation Subset:  IM    
Biostatistics Branch, National Cancer Institute, Bethesda, Maryland 20892, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Androgens / blood*
Breast Neoplasms / pathology
Clinical Chemistry Tests / standards*
Epidemiologic Studies
Laboratories / standards
Middle Aged
Reproducibility of Results
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  E2F-1: a proliferative marker of breast neoplasia.
Next Document:  Urinary pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein.